| Literature DB >> 19025654 |
Manuel Vazquez-Marrufo1, Javier J Gonzalez-Rosa, Encarnacion Vaquero, Pablo Duque, Monica Borges, Carlos Gomez, Guillermo Izquierdo.
Abstract
BACKGROUND: A possible method of finding physiological markers of multiple sclerosis (MS) is the application of EEG quantification (QEEG) of brain activity when the subject is stressed by the demands of a cognitive task. In particular, modulations of the spectral content that take place in the EEG of patients with multiple sclerosis remitting-relapsing (RRMS) and benign multiple sclerosis (BMS) during a visuo-spatial task need to be observed.Entities:
Mesh:
Year: 2008 PMID: 19025654 PMCID: PMC2628940 DOI: 10.1186/1471-2377-8-44
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Figure 1Experimental Paradigm. The onset of the imperative stimulus is on 0 milliseconds (ms). FFT: Fast Fourier Transformation Interval.
Descriptive and Statistical results of the behavioural data
| BMS | 545 ± 73 | 557 ± 65 | 551 ± 67 | 81 ± 24 | 80 ± 21 | 81 ± 22 |
| RRMS | 507 ± 57 | 525 ± 57 | 516 ± 56 | 89 ± 15 | 88 ± 15 | 89 ± 15 |
| CON | 441 ± 62 | 474 ± 66 | 457 ± 64 | 97 ± 3 | 96 ± 6 | 96 ± 4 |
| Cue | 43.007 | <0.001 | 0.275 | 0.603 | ||
| Group | 8.891 | 0.001 | 4.627 | 0.015 | ||
| Cue × Group | 3.773 | 0.030 | 0.013 | 0.987 | ||
| RRMS | 0.403 | 0.433 | 0.307 | |||
| BMS | ||||||
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group.
Figure 2Power Spectral Density (PSD) of different bands. Different colours represent every spectral band (delta (0.5 – 4 Hz): blue colour; theta (5 – 8): green; alpha (9 – 12 Hz): red; beta (13 – 30 Hz): yellow and gamma (31 – 45 Hz): white. A) Subtraction of RRMS scores from control values. B) Subtraction of BMS scores from control values. CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group.
Post Hoc results for spectral analysis of beta-2 and gamma bands
| BMS | 2.152 | 2.185 | 1.986 | 1.984 | 1.445 | 1.467 | 1.419 | 1.418 |
| RRMS | 2.487 | 2.456 | 2.457 | 2.450 | 1.944 | 1.941 | 1.873 | 1.898 |
| CON | 1.850 | 1.877 | 1.748 | 1.770 | 1.307 | 1.320 | 1.306 | 1.307 |
| BxLxHxExG | 1.941 | 0.009 | ||||||
| RRMS | 0.102 | 0.135 | ||||||
| BMS | 1.000 | 1.000 | 0.792 | 0.785 | 0.424 | 0.550 | 0.432 | 0.465 |
| BMS | 1.177 | 1.177 | 1.038 | 1.052 | 0.800 | 0.808 | 0.759 | 0.767 |
| RRMS | 1.325 | 1.290 | 1.300 | 1.289 | 1.094 | 1.085 | 1.059 | 1.040 |
| CON | 0.973 | 0.968 | 0.870 | 0.858 | 0.710 | 0.711 | 0.713 | 0.714 |
| BxLxHxExG | 1.941 | 0.009 | ||||||
| RRMS | 0.196 | 0.182 | ||||||
| BMS | 1.000 | 1.000 | 0.945 | 1.000 | 0.435 | 0.517 | 0.348 | 0.434 |
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group. Side Stimulus Location: L (Left) and R (Right).
Clinical, behavioural and quantitative EEG data from subjects participating in the study
| RRMS 1 | 32 | 4 | 2 | 587* | 1.11 | 0.59 |
| RRMS 2 | 31 | 2 | 0 | 488 | 2.37* | 1.35* |
| RRMS 3 | 41 | 4 | 1.5 | 560 | 1.03 | 0.52 |
| RRMS 4 | 29 | 2 | 1 | 540 | 1.51 | 0.84 |
| RRMS 5 | 31 | 3 | 1.5 | 436 | 2.61* | 1.44* |
| RRMS 6 | 52 | 8 | 3 | 455 | 2.76* | 1.56* |
| RRMS 7 | 53 | 18 | 2 | 473 | 1.69 | 0.84 |
| RRMS 8 | 42 | 2 | 2 | 548 | 1.06 | 0.59 |
| RRMS 9 | 38 | 3 | 2.5 | 480 | 2.98* | 1.88* |
| RRMS 10 | 35 | 5 | 1.5 | 411 | 1.3 | 0.71 |
| RRMS 11 | 46 | 6 | 3 | 493 | 1.76 | 1.01 |
| RRMS 12 | 32 | 3 | 1.5 | 552 | 1.02 | 0.53 |
| RRMS 13 | 34 | 1 | 0 | 470 | 1.68 | 0.93 |
| RRMS 14 | 41 | 5 | 1.5 | 535 | 4.87* | 2.87* |
| RRMS 15 | 29 | 5 | 1 | 536 | 2.23 | 1.14 |
| RRMS 16 | 34 | 6 | 1.5 | 547 | 2.55* | 0.97 |
| RRMS 17 | 40 | 14 | 1.5 | 587 | 2.06 | 1.1 |
| RRMS 18 | 38 | 7 | 1.5 | 642* | 2.46* | 1.2 |
| RRMS 19 | 24 | 5 | 1.5 | 552 | 2.67* | 1.59* |
| BMS 1 | 45 | 10 | 1 | 552 | 1.91 | 1.09 |
| BMS 2 | 37 | 8 | 0 | 606* | 1 | 0.45 |
| BMS 3 | 46 | 16 | 3.5 | 630* | 1.31 | 0.71 |
| BMS 4 | 56 | 11 | 2.5 | 616* | 1.96 | 1.16 |
| BMS 5 | 41 | 12 | 2 | 606* | 1.59 | 0.81 |
| BMS 6 | 37 | 14 | 2.5 | 500 | 1.7 | 0.77 |
| BMS 7 | 36 | 22 | 2.5 | 418 | 1.11 | 0.69 |
| BMS 8 | 28 | 12 | 1 | 490 | 1.95 | 0.95 |
| BMS 9 | 43 | 8 | 3.5 | 544 | 1.93 | 1.06 |
| BMS 10 | 36 | 10 | 1.5 | 544 | 1.7 | 0.97 |
| CON 1 | 32 | . | . | 433 | 2.15 | 1.15 |
| CON 2 | 31 | . | . | 406 | 1.88 | 0.9 |
| CON 3 | 23 | . | . | 526 | 1.27 | 0.66 |
| CON 4 | 35 | . | . | 489 | 2.01 | 1.11 |
| CON 5 | 31 | . | . | 430 | 1.13 | 0.58 |
| CON 6 | 54 | . | . | 476 | 1.09 | 0.56 |
| CON 7 | 38 | . | . | 398 | 1.95 | 1.12 |
| CON 8 | 33 | . | . | 507 | 1.5 | 0.81 |
| CON 9 | 35 | . | . | 495 | 1.18 | 0.67 |
| CON 10 | 51 | . | . | 484 | 1.47 | 0.68 |
| CON 11 | 26 | . | . | 382 | 1.68 | 0.89 |
| CON 12 | 36 | . | . | 342 | 1.81 | 0.94 |
| CON 13 | 42 | . | . | 522 | 1.18 | 0.69 |
| CON 14 | 35 | . | . | 505 | 1 | 0.5 |
| CON 15 | 42 | . | . | 398 | 1.46 | 0.79 |
| CON 16 | 36 | . | . | 422 | 1.09 | 0.58 |
| CON 17 | 36 | . | . | 481 | 1.33 | 0.59 |
| CON 18 | 35 | . | . | 419 | 1.35 | 0.67 |
| CON 19 | 41 | . | . | 573 | 0.9 | 0.43 |
| CON 20 | 34 | . | . | 550 | 1.73 | 0.89 |
| CON 21 | 21 | . | . | 354 | 1.41 | 0.72 |
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group. DE: Disease evolution (years); EDSS: Expanded Disability Status Scale. RT: Reaction Time (ms); BETA-2 and GAMMA (Power Spectral Density (μV2). PSD values presented in the table were obtained as an average of the three statistical significant scalp positions (F4, O1 and O2). Values with an asterisk (*) are over +2 Standard Deviation.